Zobrazeno 1 - 6
of 6
pro vyhledávání: '"D. J. Hovgaard"'
Publikováno v:
British journal of haematology. 91(2)
The pharmacokinetics and the pharmacodynamic profile of subcutaneously administered recombinant human non-glycosylated interleukin-3 (rhIL-3) was studied in lymphoma patients after standard CHOP chemotherapy. 30 patients received 0.5, 1.0, 5.0, 7.5 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5358a4965db62b42762ecf95776eece
https://pubmed.ncbi.nlm.nih.gov/8547077
https://pubmed.ncbi.nlm.nih.gov/8547077
Autor:
N. I. Nissen, D. J. Hovgaard
Publikováno v:
European journal of haematology. 54(2)
The effect of rhIL-3 was investigated in 32 patients with newly diagnosed non-Hodgkin lymphoma in a phase I/II trial. All patients received 6 cycles of standard CHOP chemotherapy, and each patient was his own control where rhIL-3 was given as a daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3fc4c67e721e636e9efa3ff0154ad4
https://pubmed.ncbi.nlm.nih.gov/7698300
https://pubmed.ncbi.nlm.nih.gov/7698300
Publikováno v:
British journal of haematology. 87(4)
Summary The pharmacokinetics of E. coli derived recombinant human interleukin-3 (rhIL-3) was studied following intravenous (i.v.) and subcutaneous (s.c.) bolus injection of rhIL-3. After i.v. bolus injection in eight patients, serum peak levels of 34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5404550565f3f0a1012060c44b49c3e5
https://pubmed.ncbi.nlm.nih.gov/7986709
https://pubmed.ncbi.nlm.nih.gov/7986709
Autor:
D J, Hovgaard
Publikováno v:
Ugeskrift for laeger. 156(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::af2eed4de3f2600796d9ce884ffbf1b4
https://pubmed.ncbi.nlm.nih.gov/8140672
https://pubmed.ncbi.nlm.nih.gov/8140672
Publikováno v:
Acta chirurgiae plasticae. 35(1-2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd190d0e1343a680fe92e10da7c87c49
https://pubmed.ncbi.nlm.nih.gov/7509552
https://pubmed.ncbi.nlm.nih.gov/7509552
Autor:
D J Hovgaard, N I Nissen
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(3)
PURPOSE As bone marrow toxicity is the major limitation of the optimal administration of chemotherapy, we investigated whether recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) could prevent myelotoxicity or accelerate hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5153217fef27633a8b75143680a76f5e
https://pubmed.ncbi.nlm.nih.gov/1740678
https://pubmed.ncbi.nlm.nih.gov/1740678